The laboratory, which has disappointed in the past and again in 2020, after having given up participating in the race for messenger RNA (mRNA) vaccines against Covid-19, is however on the right track.
The roadmap of general manager Paul Hudson, who arrived in 2019, is going well. Its primary ambition, to relaunch the group’s growth, undermined by a deterioration in its competitive positions linked to the disappearance of its blockbusters (Lantus, Plavix, etc.), is materializing.
Trend reversal
Sanofi has regained good momentum, as shown by the 8% increase (at constant exchange rates) in its sales, as of September 30. The goal of growth…
Subscribe now
Discover the survey of the week in preview every Thursday and benefit from exclusive services with Investir Ultima (round tables, Allo finance…).
To subscribe, contact our customer service
on 01 55 56 70 67 from Monday to Friday, from 9:00 a.m. to 6:00 p.m.
Already subscribed to the Ultima offer? I connect